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Abstract. The correct interpretation of metabolic response 
in cancer cells to therapy requires knowledge of how 
tumor-free tissue responds to the same treatment. The aim 
of this study was to evaluate standardized uptake values 
(SUVs) in tumor-free regions of patients with metastatic 
colorectal cancer prior to and following therapy, via the use 
of 18-fluoride fluoro-2-deoxy-D-glucose (18F-FDG) positron 
emission tomography/computed tomography (PET/CT). On 
baseline 18F-FDG PET/CT scans (n=51), volumes of interest 
(VOI) were obtained from tumor-free tissue (aortic arch, liver 
and spleen) and SUVs normalized to total body mass were 
registered. The procedure was repeated for a follow-up scan 
two weeks following a single administration of the third-
line treatment with irinotecan plus cetuximab. The mean 
differences in SUV prior to and following therapy were non-
significant (P>0.05) in all the registered tumor-free regions. 
Correlation coefficients indicated a significant result between 
the variables (0.74-0.84; P<0.001). This study suggests that 
the early assessment of metabolic response may be made 
following the administration of third-line therapy with irino-
tecan plus cetuximab in patients with metastatic colorectal 
cancer refractory to second-line treatment with irinotecan.
Introduction
With an estimated incidence of 333,330 cases in the 
European Union (2008) and reports of high mortality rates, 
colorectal cancer (CRC) is one of the most common causes of 
cancer-related mortality in the US and Europe (1). Metastatic 
disease is present in approximately 25% of patients at the time 
of diagnosis, with 50% of patients likely to develop metastases. 
The majority of these patients are unlikely to be available for 
surgical resection with a primary curative intention.
Therapy for advanced cancer, either on an individual basis 
or via clinical trials, may often be toxic to the patient and also 
costly and response rates are considered to be relatively low. 
The timely discontinuation of treatment is therefore crucial. 
The decision to continue, alter or terminate a specific treat-
ment regimen is often based upon morphological imaging. The 
RECIST criteria (2,3) have, until the introduction of positron 
emission tomography (PET), been used as a ‘gold standard’ 
for response evaluation. Imaging of glucose metabolism 
in cancer cells with quantitative PET applying the glucose 
analog 18-fluoride fluoro-2-deoxy-D-glucose (18F-FDG), 
has emerged as a powerful tool (4-6), with numerous studies 
reporting a positive correlation between the tumor 18F-FDG 
uptake immediately following or during treatment and the 
clinical outcome. Changes in tumor metabolism may be 
observed prior to changes in tumor size, providing information 
that may be used for early individual risk assessment or as an 
early surrogate endpoint in a clinical trial.
The metabolic response on an 18F-FDG PET scan may be 
determined using qualitative and quantitative approaches. The 
most common method for quantifying FDG uptake is via the 
application of standardized uptake values (SUVs), which may 
be normalized to body mass, lean body mass or body surface 
area. Being relatively easy to access, SUVs have gained popu-
larity in the clinic. Standardized protocols, including patient 
preparation, scanning procedure, image reconstruction and 
image analysis, are essential when patients are studied over a 
period of time or are participating in multicenter studies (7-10). 
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As changes in plasma glucose levels and/or differences in FDG 
plasma clearance among scans may interfere with the interpre-
tation of SUV results (11,12), factors affecting these parameters 
should also be standardized. The European Organisation for 
Research and Treatment of Cancer (EORTC), the National 
Cancer Institute (NCI) and the European Association of 
Nuclear Medicine have all made consensus recommendations 
with regard to SUV and the issues mentioned above (9,13,14). 
Although these recommendations are followed, studies 
assessing metabolic response to therapy also have to address 
the following consideration: SUVs in reproducible, tumor-free 
regions of interest (ROI) should be significantly consistent 
throughout therapy, therefore a significant change in tumor 
SUV would be indicative of a therapeutic metabolic response.
By using 18F-FDG PET/CT, the aim of this study was 
to evaluate SUVs in non-tumor volumes of interest (VOI) in 
patients with metastatic CRC refractory to second-line treat-
ment with irinotecan just prior to and 2 weeks following a 
single administration of third-line therapy with irinotecan plus 
cetuximab.
Materials and methods
Selection and description of participants. The study occurred 
at a specialist cancer treatment center. Only patients with 
metastatic CRC participated in the study. The inclusion and 
exclusion criteria are listed in Fig. 1. A total of 51 patients 
(mean body weight, 74±18 kg; range, 47-132 kg; follow-up, 
74±17 kg, range, 47-130 kg) underwent a baseline 18F-FDG 
PET/CT scan prior to a single administration of irinotecan 
(180 mg/m2) plus cetuximab (500 mg/m2). A follow-up scan 
was performed at two weeks following treatment. The proce-
dure followed was according to a protocol approved by the 
Regional Ethics Committee of Copenhagen County and with 
the Helsinki declaration (2008). Oral and written informed 
consent from the patients were obtained prior to any patient 
participating in the study.
Methods. A dose of 4 MBq/kg (maximum 400 MBq) of 18F-FDG 
was injected intravenously (i.v.) following a minimum 
6-h fast in patients with blood glucose levels <120 mg/dl. 
PET/CT data were acquired at 60 min post-injection (p.i.) 
on a GE Healthcare DiscoveryTM (Buckinghamshire, UK) 
VCT PET/CT scanner (15). A helical diagnostic CT scan was 
acquired with oral (E-Z-Cat® 0.9 l solution) and i.v. contrast 
(Ultravist® 370 mg I/ml) using a standard CT protocol with 
a scan field of view of 70 cm. Data were reconstructed with 
a standard filter into transaxial slices with a field of view 
of 50 cm, matrix size of 512x512 (pixel size 0.98 mm) and 
a slice thickness of 3.75 mm. The CT scan was followed 
immediately by a PET scan performed using a standard 
whole-body acquisition protocol with 6-7 bed positions, 
a slice overlap of 7 and an acquisition time of 2.5 min per 
bed position. The scan field of view was 70 cm. The attenu-
ation correction was based on the CT scan. The PET data 
were reconstructed into transaxial slices with a matrix size 
of 128x128 (pixel size 5.47 mm) and a slice thickness of 
3.75 mm using iterative 3D-OSEM (2 iterations, 28 subsets). 
Corrections for attenuation, randoms, dead time and normal-
ization were carried out inside the iterative loop. Analyses of 
CT, PET and fused PET/CT data were performed using a GE 
Healthcare Volume Viewer® on a GE Healthcare Advantage 
Workstation® version 4.4. Approximately 10 cm3 VOI was 
drawn in the aortic arch, in tumor-free liver and in the spleen 
and SUVs (maximum and mean) normalized to total body 
mass were registered for all regions. Baseline and follow-up 
data were obtained using the same PET/CT scanner. To avoid 
possible inter-observer bias, the same physician analyzed all 
scans (16,17).
Statistical analysis. Calculations of sample size and power 
were performed using the Altman nomogram (18). The 
minimal relevant difference (MIREDIF) in SUV was set to 
be equal to the standard deviation, yielding a standardized 
difference of 1.0. The power of the study was determined to 
be 0.94. Any other statistical analyses were performed using 
MedCalc 11.1.1® (Mariakerke, Belgium) and SPSS Statistics 
17.0® (Chicago, IL, USA). The SUV results were compared 
with Gaussian distributions by applying the D'Agostino-
Pearson omnibus test (19,20). The SUV measurements passed 
the test for normality (P>0.05). Paired samples t-test was used 
to compare two sets of results to assess whether there was any 
difference between the means. Correlation coefficients were 
calculated to measure the strength of correlation between 
variables. P<0.05 was considered to indicate a statistically 
significant result.
Results
The results of this study showed significantly consistent SUVs 
(SUVmax and SUVmean) in the aortic arch, liver and spleen 
Figure 1. Criteria for inclusion and exclusion.
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tumor-free regions prior to and 2 weeks following a single 
administration of third-line treatment with irinotecan plus 
cetuximab in patients with irinotecan refractory metastatic 
CRC (Tables I and II).
The mean differences were non-significant (P>0.05; 
Table III) in the aortic arch, liver and spleen regions of interest 
and SUVmax and SUVmean. The correlation coefficients were 
significant (P<0.001; Table III), ranging from 0.74 to 0.84.
Discussion
Semi-quantitative analysis of glucose metabolism in tumors 
with 18F-FDG PET in the prediction of clinical outcome is 
gaining popularity (4-6), due to the evidence that changes in 
tumor metabolism may be observed prior to changes in tumor 
size. Knowledge of how tumor-free tissue responds to the 
same treatment regimen is required for the correct interpreta-
tion of metabolic response in cancer cells to therapy. Thus, 
a significant change in tumor SUV would be indicative of 
a therapeutic metabolic response if SUVs in reproducible, 
non-tumor ROI are consistent throughout therapy. Response 
rates to therapy for metastatic colorectal cancer are markedly 
low and a swift individual assessment for different treatment 
regimens is crucial.
Assuming all consensus recommendations with regard to 
data acquisition and patient preparation are fulfilled (9,13,14), 
this study demonstrates significantly consistent SUVs (both 
SUVmax and SUVmean) in three different tumor-free regions 
(aortic arch, liver and spleen) prior to and 2 weeks following 
a single administration of third-line treatment with irinotecan 
plus cetuximab in patients with irinotecan refractory meta-
static CRC. This study provides the fundamental data needed 
for studies focusing on the early assessment of therapeutic 
response in these patients with this specific treatment regimen. 
Table II. SUVs following treatment.
Region (10 cm3 VOI) Mean ± SD CI (95%)
Aortic arch SUVmax 1.70±0.48 1.57-1.83
Aortic arch SUVmean 1.20±0.34 1.10-1.29
Liver SUVmax  2.12±0.55 1.96-2.27
Liver SUVmean 1.59±0.41 1.47-1.71
Spleen SUVmax 1.89±0.54 1.74-2.04
Spleen SUVmean 1.35±0.39 1.24-1.46
N=51. SUV, standardized uptake value; SD, standard deviation; 
CI, confidence interval; VOI, volume of interest.
Table III. Comparison of SUV prior to and following treatment (paired samples t-test and test of correlation).
Region (10 cm3 VOI) Mean difference ± SD CI (95%) P-value Correlation P-value
Aortic arch SUVmax -0.045±0.32 -0.135-0.045 0.32 0.74 <0.001a
Aortic arch SUVmean -0.022±0.23 -0.086-0.042 0.50 0.74 <0.001a
Liver SUVmax  0.010±0.30 -0.074-0.094 0.82 0.84 <0.001a
Liver SUVmean -0.006±0.26 -0.080-0.068 0.87 0.77 <0.001a
Spleen SUVmax 0.053±0.33 -0.145-0.039 0.25 0.80 <0.001a
Spleen SUVmean -0.004±0.24 -0.072-0.064 0.91 0.80 <0.001a
N=51. aP<0.05 was considered to indicate a statistically significant result. SUV, standardized uptake value; SD, standard deviation; 
CI, confidence interval; VOI, volume of interest.
Table I. Baseline SUVs prior to treatment.
Region (10 cm3 VOI) Mean ± SD CI (95%) Normal distribution (P-value)
Aortic arch SUVmax 1.66±0.37 1.55-1.76 0.66
Aortic arch SUVmean 1.18±0.26 1.10-1.25 0.66
Liver SUVmax  2.13±0.50 1.99-2.27 0.16
Liver SUVmean 1.58±0.34 1.49-1.68 0.62
Spleen SUVmax 1.83±0.48 1.70-1.97 0.07
Spleen SUVmean 1.35±0.36 1.25-1.45 0.33
N=51. P<0.05 was considered to indicate a statistically significant result. Data were tested for normal distribution using the D'Agostino-Pearson 
omnibus test. SUV, standardized uptake value; SD, standard deviation; CI, confidence interval; VOI, volume of interest.
ANDERSEN et al:  IMPACT OF TREATMENT WITH IRINOTECAN PLUS CETUXIMAB ON NON-TUMOR SUV134
References
 1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of 
cancer incidence and mortality in Europe in 2008. Eur J Cancer 
46: 765-81, 2010.
 2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, 
Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, 
et al: New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 
2009.
 3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, 
Rubinstein L, Verweij J, Van GM, van Oosterom AT, 
Christian MC and Gwyther SG: New guidelines to evaluate the 
response to treatment in solid tumors. European Organization 
for Research and Treatment of Cancer, National Cancer Institute 
of the United States, National Cancer Institute of Canada. J Natl 
Cancer Inst 92: 205-216, 2000.
 4. Kidd EA, Siegel BA, Dehdashti F and Grigsby PW: The stan-
dardized uptake value for F-18 fluorodeoxyglucose is a sensitive 
predictive biomarker for cervical cancer treatment response and 
survival. Cancer 110: 1738-1744, 2007.
 5. Larson SM and Schwartz LH: 18F-FDG PET as a candidate 
for ‘qualified biomarker’: functional assessment of treatment 
response in oncology. J Nucl Med 47: 901-903, 2006.
 6. Weber WA: Positron emission tomography as an imaging 
biomarker. J Clin Oncol 24: 3282-3292, 2006.
 7. Boellaard R: Standards for PET image acquisition and quanti-
tative data analysis. J Nucl Med 50 (Suppl 1): S11-S20, 2009.
 8. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, 
Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA 
and Boellaard R: Measuring response to therapy using FDG PET: 
semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol 
Imaging, January 6, 2011 (Epub ahead of print).
 9. Shankar LK, Hoffman JM, Bacharach S, Graham MM, 
Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, 
Van den Abbeele A, Yap J and Sullivan D: Consensus recom-
mendations for the use of 18F-FDG PET as an indicator of 
therapeutic response in patients in National Cancer Institute 
Trials. J Nucl Med 47: 1059-1066, 2006.
10. Weber WA: Use of PET for monitoring cancer therapy and for 
predicting outcome. J Nucl Med 46: 983-995, 2005.
11. Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, 
Whatley M, Carson JM, Sellers D, Libutti SK, Yang JC and 
Bacharach SL: Comparison of SUV and Patlak slope for moni-
toring of cancer therapy using serial PET scans. Eur J Nucl Med 
Mol Imaging 30: 46-53, 2003.
12. Huang SC: Anatomy of SUV. Standardized uptake value. Nucl 
Med Biol 27: 643-646, 2000.
13. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, 
Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, 
Hoekstra OS, Pruim J, et al: FDG PET and PET/CT: EANM 
procedure guidelines for tumour PET imaging: version 1.0. Eur J 
Nucl Med Mol Imaging 37: 181-200, 2010.
14. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, 
Lammertsma AA, Pruim J and Price P: Measurement of clinical 
and subclinical tumour response using [18F]-fluorodeoxyglucose 
and positron emission tomography: review and 1999 EORTC 
recommendations. European Organization for Research and 
Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 
35: 1773-1782, 1999.
15. Teräs M, Tolvanen T, Johansson JJ, Williams JJ and Knuuti J: 
Performance of the new generation of whole-body PET/CT 
scanners: Discovery STE and Discovery VCT. Eur J Nucl Med 
Mol Imaging 34: 1683-1692, 2007.
16. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, 
Phelps ME, Czernin J and Weber WA: Treatment monitoring by 
18F-FDG PET/CT in patients with sarcomas: interobserver vari-
ability of quantitative parameters in treatment-induced changes 
in histopathologically responding and nonresponding tumors. 
J Nucl Med 49: 1038-1046, 2008.
17. Marom EM, Munden RF, Truong MT, Gladish GW, Podoloff DA, 
Mawlawi O, Broemeling LD, Bruzzi JF and Macapinlac HA: 
Interobserver and intraobserver variability of standardized 
uptake value measurements in non-small-cell lung cancer. 
J Thorac Imaging 21: 205-212, 2006.
18. Altman DG: Statistics and ethics in medical research: III How 
large a sample? Br Med J 281: 1336-1338, 1980.
19. D'Agostino RB and Pearson ES: Tests for departure from 
normality. Empirical results for the distributions of b2 and √b1. 
Biometrika 60: 613-622, 1973.
20. D'Agostino RB and Stephens MA (eds): Goodness-of-Fit 
Techniques. Marcel Dekker, New York, 1986.
